Pharmaceutical industry: 9 billion dollar deal: Sanofi buys US pharmaceutical company

The French drug manufacturer Sanofi wants to strengthen its business with rare immunological diseases with a billion dollar takeover of the US pharmaceutical company Blueprint Medicines. Sanofi will pay $ 129 per share in cash or $ 9.1 billion (around 8 billion euros), the company said in Paris. This corresponds to a surcharge of 27 percent on the final course of Blueprint on Friday.

“The planned takeover of Blueprint Medicines represents a strategic step forward in our portfolios for rare medicines and immunology,” said Sanofi boss Paul Hudson. “It extends our pipeline and accelerates our transformation to the world’s leading immunology company.”

Medicine for rare immune diseases

By buying, the company receives the medication Avapritinib approved in the USA and the EU for the treatment of rare immune diseases and a promising pipeline of immunology products. Avapritinib is the only approved remedy for a rare immune disease in which changing mast cells in the bone marrow, the skin, the digestive tract and other organs accumulate and become active.

According to Sanofi, the Blueprint shareholders can also receive additional milestone payments if a certain medication candidate reaches certain levels of development. Then the evaluation would increase to up to $ 9.5 billion. The takeover should be completed in the third quarter and have no significant influence on the financial forecast of Sanofi for 2025. Sanofi is currently rated around 107 billion euros on the stock exchange.